티빅 헬스 시스템즈(TIVC)는 NASDAQ에 상장된 Healthcare · Medical Devices 기업입니다. 현재가 $2.23 (+7.21%), 시가총액 $0.00B, 52주 최저~최고 $0.74 ~ $4.45.
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
티빅 헬스 시스템즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
티빅 헬스 시스템즈의 현재 주가는 $2.23 (+7.21%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
티빅 헬스 시스템즈의 시가총액은 약 $0.00B입니다.
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The comp